Neuropore Abstracts and Publications

  1. Price DL, Paulino AD, Gonzalez-Ruelas T, Ubhi K, Rockenstein E, Tsigelny I, Wrasidlo W, Moessler H, Masliah E (2011) Novel structure based designed compound reduces accumulation of toxic alpha-synuclein and improves deficits in a transgenic murine model of PD/DLB. Society for Neuroscience, Abstract 357.25.
  2. Price DL, Wrasidlo W, Tsigelny I, Bonhaus D, Paulino AD, Mante M, Inglis C, Adame A, Moessler H, Rockenstein E, Masliah (2012) Neuroprotective effects of a novel abeta-protein stabilizer in an APP transgenic mouse model of Alzheimer's disease. AAIC, Abstract No. 29624, Vancouver, B.C.
  3. Reznichenko L, Cheng Q, Mante M, Saisan PA, Rockenstein EM, Overk C, Tsigelny IF, Wrasidlo W, Price DL, Dale AM, Devor A, Masliah E (2012) Novel organic compound targeting misfolded α-synuclein normalized calcium abnormalities in α-synuclein transgenic Parkinson’s Disease-like mouse model. (2012) Society for Neuroscience, Abstract 53.2.
  4. Wrasidlo W, Tsigelny I, Price DL, Bonhaus DW, Paulino AD, Moessler H, Rockenstein E, Masliah E (2013) Development of a Novel Series of PI3K Modulators Designed to Promote Autophagy and the Cellular Clearance of Neurotoxic Peptides. International Conference on AD/PD, Abstract, Florence, Italy.
  5. Price DL, Overk CR, Wrasidlo W, Tsigelny I, Bonhaus D, Paulino AD, Rockenstein E, Masliah E (2013) In vivo two-photon imaging of alpha-synuclein: Effects of a novel alpha-synuclein stabilizer in an eGFP-alpha-synuclein transgenic mouse model of Lewy Body disease. Society for Neuroscience, Abstract 329.15.
  6. Rockenstein EM, Price DL, Mante M, Masliah E (2013) Retinal scanning evaluations of alpha-synuclein-eGFP deposition in a transgenic mouse model of PD/DLB. Society for Neuroscience, Abstract 329.06.
  7. Szoke B, Wrasidlo W, Stocking E, Tsigelny I, Schwartz TC, Konrat R, Gaspar D, Veiga AS, Paulino AD, Price DL, Winter S, Masliah E, Bonhaus D, Meier D (2014) Biophysical characterization of the interaction of NPT200-11 with alpha-synuclein. Society for Neuroscience, Abstract 411.04.
  8. Rockenstein EM, Price DL, Bonhaus DW, Mante M, Lindsey JD, Masliah E (2014) Live imaging of alpha-synuclein aggregates in the retina of alpha-synuclein-GFP transgenic mice as a marker of alpha-synuclein pathology in the brain. Society for Neuroscience, Abstract 411.05.
  9. Koike MA, Price DL, White BM, Rockenstein E, Wrasidlo W, Tsigelny I, Meier D, Masliah E, Bonhaus D (2014) The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology, and biochemistry in the murine thy1-ASYN transgenic model of Parkinson’s disease. Society for Neuroscience, Abstract 411.06.
  10. Price DL, Rockenstein E, Mante M, Wrasidlo W, Masliah E, Bonhaus DW, Meier DH (2014) The novel alpha-synuclein stabilizer NPT200-11 reduces retinal deposits of ASYN-eGFP in a transgenic mouse model of Parkinson’s disease/Lewy body disease. Society for Neuroscience, Abstract 411.07.
  11. Price DL, Rockenstein E, Bonhaus D, Masliah E (2014) Validation of retinal imaging for characterizing alpha-synuclein-eGFP deposition in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies. White paper web-published in collaboration with Phoenix Research Laboratories.
  12. Lister D, West M, Flecha A, Price DL, Rockenstein E, Masliah E and McConville P (2015) "Translational imaging biomarkers in rodent models of Parkinson's": 123I‐ioflupane SPECT/CT imaging of the dopamine transporter and 18F‐FDG PET/CT imaging of metabolism. World Molecular Imaging Congress, Honolulu Hawaii.
  13. Price DL, Rockenstein E, Mante M, Adame A, Overk C, Spencer B, Duong-Polk KX, Bonhaus D, Lindsey J, Masliah E (2016) Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies. Scientific Reports, 6:29523.
  14. Gillman AL,Lee J, Ramachandran S, Capone R, Gonzalez T, Wrasidlo W, Masliah E, Lal R (In Press) Small molecule NPT-440-1 inhibits ionic flux through Aβ1-42 pores: Implications for Alzheimer's disease therapeutics. Nanomedicine: Nanotechnology, Biology, and Medicine.
  15. Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik AA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, Trejo-Morales M, Overk CR, Winter S, Zhu C, Chesselet M-F, Meier D, Moessler H, Konrat R, Masliah E (2016) A De Novo Compound Targeting Alpha-Synuclein Improves Deficits In Models of Parkinson’s Disease. Brain (Advance Access published online September 27, 2016).
  16. Kouroupi G, Taoufik E, Vlachos IS,Tsioras K, Antoniou N, Papastefanaki F, Chroni-Tzartou D, Wrasidlo W,  Bohl D, Stellas D, Politis PK, Vekrellis K, Papadimitriou D, Stefanis L, Bregestovski P, Hatzigeorgiou AG, Masliah E, Matsas R (2017) Defective synaptic connectivity and axonalneuropathology in a human iPSC-based model of familial Parkinson’s disease.  Proc Natl Acad Sci U S A, 114(18) E3679-E3688.

Key references 

Here we provide links to conduct up to date PubMed searches on key authors and topics related to Neuropore science and drug discovery efforts:

  • Click here to retrieve all articles published by Dr. Eliezer Masliah
  • Click here to retrieve all articles published for alpha-synuclein
  • Click here to retrieve all articles published for synucleinopathies
  • Click here to retrieve all articles published for amyloid-beta
  • Click here to retrieve articles published for autophagy
  • Click here to retrieve articles published for TLR2